13F Holdings
中文EN

UTHR UNITED THERAPEUTICS Corp

Pharmaceutical Preparations · Nasdaq · SEC CIK 1082554 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.9%
TTM net income YoY-3.2%
TTM EPS YoY0.4%
Revenue 3-yr CAGR13.1%
Net income 3-yr CAGR11.0%

Margins

Gross margin86.3%
Operating margin41.4%
Net margin38.6%
FCF margin27.2%
EBITDA margin44.5%

Returns

ROE19.1%
ROA17.1%
ROIC (approx.)20.9%
Asset turnover0.44x

Leverage & solvency

Liabilities / assets10.8%
Debt / equity0.00x
Current ratio4.61x
Interest coverage111.02x

Cash quality & payout

Operating cash flow / net income1.16x
Accruals ratio-2.8%
Payout ratio—
Capex / revenue17.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$3.18B$2.88B$2.33B$1.94B$1.69B
Cost of revenue$384.40M$309.70M$257.50M$151.60M$122.50M
Gross profit$2.80B$2.57B$2.07B$1.78B$1.56B
R&D expense$550.00M$481.00M$408.00M$322.90M$540.10M
SG&A expense$755.80M$709.70M$477.10M$482.10M$467.00M
Operating income$1.49B$1.38B$1.18B$979.70M$555.90M
Interest expense$19.50M$42.90M$59.30M$32.40M$18.60M
Pretax income$1.71B$1.54B$1.27B$950.60M$593.90M
Income tax$379.20M$343.90M$289.50M$223.30M$118.10M
Net income$1.33B$1.20B$984.80M$727.30M$475.80M
EBITDA$1.58B$1.45B$1.24B$1.03B$605.80M
EPS (basic)30.1326.4421.0415.9810.60
EPS (diluted)27.8624.6419.8115.0010.06
Weighted avg. shares (diluted)47.90M48.50M49.70M48.50M47.30M
Balance sheet
Cash & equivalents$1.56B$1.70B$1.21B$961.20M$894.80M
Short-term investments$1.36B$1.57B$1.79B$1.88B$1.04B
Receivables$350.20M$279.30M$278.90M$220.40M$198.70M
Inventory$183.10M$157.90M$111.80M$102.00M$93.80M
Current assets$3.70B$3.87B$3.55B$3.38B$2.32B
PP&E, net$1.73B$1.22B$1.05B$861.50M$780.90M
Goodwill$32.30M$32.30M$33.70M$28.00M$28.00M
Total assets$7.88B$7.36B$7.17B$6.04B$5.17B
Current liabilities$560.60M$738.10M$804.40M$343.20M$305.40M
Total liabilities$783.80M$920.00M$1.18B$1.25B$1.21B
Shareholders' equity$7.10B$6.44B$5.98B$4.80B$3.96B
Shares outstanding43.64M44.83M47.04M46.03M45.11M
Cash flow statement
Operating cash flow$1.56B$1.33B$978.00M$802.50M$598.20M
Capital expenditure$520.50M$246.50M$230.40M$138.80M$120.80M
Free cash flow$1.04B$1.08B$747.60M$663.70M$477.40M
Investing cash flow-$551.30M$417.20M-$719.60M-$811.50M-$486.90M
Financing cash flow-$1.15B-$1.25B-$11.90M$75.40M$44.80M
Depreciation & amortization$85.60M$72.50M$53.20M$51.30M$49.90M
Stock-based compensation$147.70M$144.00M$39.10M$106.80M$138.50M
Share buybacks$1.00B$1.00B$0$0—

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.